{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:54:04Z","timestamp":1784901244919,"version":"3.55.0"},"reference-count":6,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Concern over variant Creutzfeldt\u2013Jakob disease (vCJD) led to the deferral of donors who had resided in the United Kingdom since January 1980. This deferral was implemented in 1999 and subsequently modified to include other countries. Some deferrals were removed in February 2022; deferrals for the United Kingdom, Ireland and France were removed on 22 November 2023. In this study, we describe efforts made to encourage donation from newly eligible people and the resulting donation gain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Actions targeted individual donors deferred after 1 January 2012. Marketing included website, social media and general advertising. Staff asked first\u2010time donors if the criteria change had motivated their donation. Deferred and returning donor data were determined from our donor database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 12\u2009months post\u2010implementation, 12.8% of first\u2010time donors surveyed were newly eligible (<jats:italic>n<\/jats:italic>\u2009=\u20098667) and 7.8% of vCJD risk deferred donors returned (<jats:italic>n<\/jats:italic>\u2009=\u20095159). Eighty\u2010five percent of deferrals occurred pre\u20102017; the return rate was 6.5% in this group. The highest return rate (24%) occurred in donors deferred after 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Removal of the vCJD deferrals had a major positive impact. The greatest gain was in new donors who had previously self\u2010deferred. Despite intensive efforts, only one\u2010quarter of recently deferred donors returned.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.70021","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T06:47:55Z","timestamp":1742885275000},"page":"635-638","source":"Crossref","is-referenced-by-count":1,"title":["Removal of deferrals for variant Creutzfeldt\u2013Jakob disease risk: Impact on new and previously deferred donors"],"prefix":"10.1111","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-9952","authenticated-orcid":false,"given":"Mindy","family":"Goldman","sequence":"first","affiliation":[{"name":"Canadian Blood Services, Medical Affairs and Innovation  Ottawa Ontario Canada"},{"name":"Department of Pathology and Laboratory Medicine University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McKee","sequence":"additional","affiliation":[{"name":"Canadian Blood Services, Enterprise Program Management  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Smith","sequence":"additional","affiliation":[{"name":"Canadian Blood Services, Operational Excellence  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2789","authenticated-orcid":false,"given":"Sheila F.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Canadian Blood Services, Medical Affairs and Innovation  Ottawa Ontario Canada"},{"name":"School of Epidemiology and Public Health University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12631"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00744.x"},{"key":"e_1_2_9_4_1","first-page":"26","article-title":"Variant Creutzfeldt\u2010Jakob disease deferral in Canada: impact of stop dates","volume":"16","author":"O'Brien SF","year":"2016","journal-title":"Blood Transfus"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13493"},{"key":"e_1_2_9_6_1","unstructured":"Recommendations to Reduce the Possible Risk to Transmission of Creutzfeldt\u2010Jakob Disease and Variant Creutzfeldt\u2010Jakob Disease by Blood and Blood Components.2022. Guidance for Industry. Food and Drug Administration. Available from:https:\/\/www.fda.gov\/media\/124156\/download#:~:text=As%20a%20precaution%2C%20we%20recommend based%20on%20post%2Ddonation%20information. Last accessed 2 Jan 2025."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13510"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:49:39Z","timestamp":1750819779000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/vox.70021"],"URL":"https:\/\/doi.org\/10.1111\/vox.70021","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}